Search Result

Results for "

5'UTR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (4) Aryl Hydrocarbon Receptor (1) Bcl-2 Family (1) DNA/RNA Synthesis (4) Eukaryotic Initiation Factor (eIF) (2) HIF/HIF Prolyl-Hydroxylase (1) HIV (1) Ligands for Target Protein for PROTAC (1) Microtubule/Tubulin (1) p38 MAPK (1) PI3K (1) PROTACs (1) Ras (1) Reference Standards (1) SARS-CoV (3) Small Interfering RNA (siRNA) (3) Target Protein Ligand-Linker Conjugates (1) Urotensin Receptor (4) Wnt (1) α-synuclein (2)
By Research Areas:	Cancer (8) Cardiovascular Disease (4) Infection (6) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (4)
Click Chemistry:	Azide (1) Alkynes (1)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (3)

Inhibitors & Agonists

Peptides

Natural
Products

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10664

SB-611812	Urotensin Receptor	Cardiovascular Disease
SB-611812 is a urotensin II receptor (UTR) antagonist with the potential in the research of cardiovascular disease .

HY-112163A

rel-Zotatifin rel-eFT226	Eukaryotic Initiation Factor (eIF) SARS-CoV Apoptosis	Infection Cancer
rel-Zotatifin is the racemic isomer of Zotatifin, acts as an eIF4A inhibitor with activity less than Zotatifin. Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC₅₀=2 nM) and interferes with the assembly of the eIF4F initiation complex .

HY-136748

HIF-2α-IN-4 1 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-2α-IN-4 is a potent inhibitor of hypoxia inducible factor-2α (HIF-2α) translation, with an IC₅₀ of 5 μM. HIF-2α-IN-4 decreases both constitutive and hypoxia-induced HIF-2α protein expression. HIF-2α-IN-4 links its 5'UTR iron-responsive element to oxygen sensing .

HY-112163

Zotatifin Maximum Cited Publications 8 Publications Verification eFT226	Eukaryotic Initiation Factor (eIF) SARS-CoV Apoptosis	Infection Cancer
Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC₅₀=2 nM) and interferes with the assembly of the eIF4F initiation complex . Zotatifin shows robust antiviral effects, it effectively reduces viral infectivity by inhibiting SARS-CoV-2 NP protein biogenesis (IC₉₀=37 nM) . Zotatifin induces cell apoptosis .

HY-168326

Antiproliferative agent-64	DNA/RNA Synthesis Microtubule/Tubulin	Cancer
Antiproliferative agent-64 (Compound 76) is an inhibitor for eukaryotic translation initiation factor 4E (eIF4E), that block the secondary structure of mRNA, thereby inhibiting protein translation. Antiproliferative agent-64 inhibits the 5' untranslated region (5'UTR) of c-Myc (c-myc 5'UTR) with an EC₅₀ of 1.2 nM, inhibits 5'UTR encoding tubulin (tub 5'UTR) with an EC₅₀ of 40 nM. Antiproliferative agent-64 inhibits the proliferation of MDA-MB-231 with an EC₅₀ of 7 nM .

HY-P11258

UPG-108	Urotensin Receptor	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
UPG-108, a peptide compound, is a non-competitive allosteric modulator of Urotensin II receptors (UTR). UPG-108 significantly enhances the efficacy of UTR agonists but reduces the potency of UTR agonists. UPG-111 efficiently induces calcium release and does not cause contraction of rat aortic rings without endothelial denudation. UPG-111 can be used to study various diseases related to the angiotensinergic system .

HY-RS15584

UTS2R Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
UTS2R Human Pre-designed siRNA Set A contains three designed siRNAs for UTS2R gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

UTS2R Human Pre-designed siRNA Set A UTS2R Human Pre-designed siRNA Set A

HY-RS15585

Uts2r Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Uts2r Mouse Pre-designed siRNA Set A contains three designed siRNAs for Uts2r gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Uts2r Mouse Pre-designed siRNA Set A Uts2r Mouse Pre-designed siRNA Set A

HY-401209

Synucleozid-2.0	α-synuclein DNA/RNA Synthesis	Neurological Disease
Synucleozid-2.0 is a small-molecule inhibitor targeting the iron-responsive element (IRE) structure in the 5' untranslated region (5'UTR) of SNCA mRNA. Synucleozid-2.0 inhibits ribosome assembly onto SNCA mRNA and selectively reduces α-synuclein protein translation. Synucleozid-2.0 is promising for research of Parkinson's disease (PD) and related α-synucleinopathies .

HY-P11259

UPG-111	Urotensin Receptor	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
UPG-111 is a peptide compound that acts as a negative allosteric modulator of the Urotensin II receptor (UTR). UPG-111 exhibits a dual inhibitory effect on the vasoconstriction induced by UTR agonists - it reduces both the maximum response intensity and the sensitivity of the agonist. UPG-111 does not induce calcium release or cause contraction of the endothelium-deprived rat aortic rings. UPG-111 can be used for the study of various diseases related to the angiotensinergic system .

HY-N10295

Flavipin	Aryl Hydrocarbon Receptor	Inflammation/Immunology
Flavipin is an aryl hydrocarbon receptor (Ahr) agonist that induces the expression of Ahr downstream genes in mouse CD4 ⁺ T cells and CD11b ⁺ macrophages. Flavipin inhibits the stabilizing function of Arid5a on Il23a 3′UTR, a newly identified target mRNA . Flavipin exhibits the DPPH free radical scavenging ability with IC₅₀ value of 7.2 μM, and has potent α-glucosidase inhibition with IC₅₀ value of 33.8 μM .

HY-125984

Syn-516	α-synuclein	Neurological Disease
Syn-516 is an inhibitor of α-synuclein (α-Syn). Syn-516 targets the 5' untranslated region (5'UTR) of α-Syn mRNA, with an IC₅₀ value of 1.8 μM, thereby inhibiting the translation process of α-Syn. Syn-516 improves motor dysfunction and colonic motility abnormalities associated with α-Syn overexpression in mouse models. α-Syn can be used to study diseases such as Parkinson's disease and Lewy body dementia .

HY-RS13011

SLC14A2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SLC14A2 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC14A2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SLC14A2 Human Pre-designed siRNA Set A SLC14A2 Human Pre-designed siRNA Set A

HY-112591

NSC260594 XMH95	Apoptosis HIV Wnt Bcl-2 Family	Cancer
NSC260594 induces Apoptosis. NSC260594 binds the shallow groove of the Mcl-1 protein, and inhibits Mcl-1 expression through down-regulation of Wnt signaling proteins. NSC260594 can also recognize G9-G10-A11-G12 RNA tetraloop of HIV and prevent the binding of the Gag protein within the 5’-UTR. NSC260594 inhibits tumor growth, and can be used for research of Triple-negative breast cancers (TNBCs) .

HY-10664R

SB-611812 (Standard)	Reference Standards Urotensin Receptor	Cardiovascular Disease
SB-611812 (Standard) is the analytical standard of SB-611812. This product is intended for research and analytical applications. SB-611812 is a urotensin II receptor (UTR) antagonist with the potential in the research of cardiovascular disease .

HY-163299

pan-KRAS-IN-5	Ras Apoptosis PI3K Akt p38 MAPK	Cancer
pan-KRAS-IN-5 is a pan-KRAS translation inhibitor by targeting 5′-UTR RNA G-quadruplexes (rG4s). pan-KRAS-IN-5 strongly binds to and stabilizes KRAS rG4s, inhibits KRAS translation, and blocks the MAPK and PI3K-AKT pathways. pan-KRAS-IN-5 induces cell cycle arrest, prompts apoptosis in KRAS-driven cancer cells. pan-KRAS-IN-5 inhibits tumor growth and KRAS expression in KRAS-mutant xenograft. KRAS-IN-5 can be used for KRAS-driven cancer research .

HY-135902

Synucleozid NSC 377363	DNA/RNA Synthesis	Neurological Disease
Synucleozid (NSC 377363) is a potent inhibitor of the SNCA mRNA that encodes α-synuclein protein. Synucleozid selectively targets the α-synuclein mRNA 5′ UTR at the designed IRE site, decreases the amount of SNCA mRNA loaded into polysomes and thereby inhibits SNCA translation. Synucleozid has the potential for the investigation of Parkinson’s disease .

HY-135902A

Synucleozid hydrochloride 1 Publications Verification NSC 377363 hydrochloride	DNA/RNA Synthesis	Neurological Disease
Synucleozid hydrochloride (NSC 377363 hydrochloride) is a potent inhibitor of the?SNCA?mRNA?that encodes α-synuclein protein. Synucleozid selectively?targets the?α-synuclein?mRNA 5′ UTR at the designed IRE site, decreases the amount of?SNCA?mRNA loaded into polysomes and thereby inhibits?SNCA?translation. Synucleozid has the potential for the investigation of Parkinson’s disease .

HY-168456

RNA recruiter 1	Ligands for Target Protein for PROTAC	Infection
RNA recruiter 1 is the RNA ligand of RNAse L RIBOTAC (HY-168456), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNA recruiter 1 can be utilized in the synthesis of RIBOTAC .

HY-168458

RNA recruiter-linker 1	Target Protein Ligand-Linker Conjugates	Infection
RNA recruiter-linker 1 is the RNA ligand-linker part of RNAse L RIBOTAC (HY-168455), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNA recruiter-linker 1 can be utilized in the synthesis of RIBOTAC .

HY-168457

RNase L ligand 2	SARS-CoV	Infection
RNase L ligand 2 (compound 6) is the Rnase L ligand part of RNAse L RIBOTAC (HY-168455), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNase L ligand 2 can be used in the synthesis of RIBOTAC .

HY-168455

RNAse L RIBOTAC	PROTACs	Infection
RNAse L RIBOTAC (compound C64) is an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. (Blue: RNA ligand (HY-168456); Black: linker (HY-130591); Pink: Rnase L ligand (HY-168457))

Cat. No.	Product Name	Target	Research Area